Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQV9 | ISIN: US68235C2061 | Ticker-Symbol: 7OC0
NASDAQ
27.06.25 | 21:59
3,180 US-Dollar
-5,64 % -0,190
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INSIGHT MOLECULAR DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
INSIGHT MOLECULAR DIAGNOSTICS INC 5-Tage-Chart

Aktuelle News zur INSIGHT MOLECULAR DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoiMDx transplant test shows equivalence to commercial alternatives2
MoInsight Molecular Diagnostics Inc.: iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing3
17.06.Oncocyte changes name to Insight Molecular Diagnostics and moves headquarters to Nashville3
17.06.Oncocyte Corp - 8-K, Current Report1
17.06.Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville1.319New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ research-use-only kits at transplant labs globallyExhibiting...
► Artikel lesen
INSIGHT MOLECULAR DIAGNOSTICS Aktie jetzt für 0€ handeln
19.05.Oncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship Technology92New price of $2,753 for the GraftAssureCore assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for...
► Artikel lesen
13.05.Needham maintains Buy on OncoCyte, price target at $4.251
13.05.OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative2
12.05.OncoCyte GAAP EPS of -$0.26 misses by $0.02, revenue of $2.13M beats by $2M1
12.05.Oncocyte Corp - 10-Q, Quarterly Report1
12.05.Oncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business Progress266Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are...
► Artikel lesen
12.05.Oncocyte Corp - 8-K, Current Report1
30.04.Oncocyte advances toward clinical trial for transplant test1
30.04.Oncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial Progress181Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual...
► Artikel lesen
29.04.Oncocyte-Studie verbindet Bluttest mit Nierentransplantat-Abstoßungsmarkern1
17.04.Oncocyte Corp - 8-K, Current Report1
31.03.Oncocyte Corp - S-1, General form for registration of securities2
28.03.OncoCyte a new buy at Lake Street on transplant rejection testing3
28.03.Lake Street starts OncoCyte coverage with Buy, $5 target1
25.03.Needham maintains Buy on OncoCyte, steady $4.25 target1
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1